Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer

Código QR

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer

The epidermal growth factor receptor (EGFR) is one of the most well-studied molecular targets in non-small cell lung cancer (NSCLC) and tyrosine kinase inhibitors have been shown to be effective in the treatment of advanced NSCLC. Nevertheless, the efficacy of tyrosine kinase inhibitors could be com...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cristina Minnelli, Laura Cianfruglia, Emiliano Laudadio, Giovanna Mobbili, Roberta Galeazzi, Tatiana Armeni
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	epigallocatechin-3-gallate (EGCG) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) non-small cell lung cancer (NSCLC) Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/cc12df14e2144e8fb730cf9ee4e75cc1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

(-)-Epigallocatechin-3-gallate Ameliorates Intervertebral Disc Degeneration Through Reprogramming of the Circadian Clock
por: Liangwei Mei, et al.
Publicado: (2021)

Role of Epigallocatechin Gallate in Glucose, Lipid, and Protein Metabolism and L-Theanine in the Metabolism-Regulatory Effects of Epigallocatechin Gallate
por: Ling Lin, et al.
Publicado: (2021)

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief
por: Huang HY, et al.
Publicado: (2018)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Evaluating the Effects of Epigallocatechin-3-Gallate on HIF-1α Protein and RORC Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis
por: Boshra Afshar, et al.
Publicado: (2021)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Cytoprotective roles of epigallocatechin gallate and resveratrol on staurosporine-treated mesenchymal stem cells in in vitro culture
por: Burczak Arkadiusz, et al.
Publicado: (2021)

Anti-osteoclastogenic effect of epigallocatechin gallate-functionalized gold nanoparticles in vitro and in vivo
por: Zhu S, et al.
Publicado: (2019)

Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
por: Chang CY, et al.
Publicado: (2016)

Preparation and Evaluation of Starch Hydrogel/Contact Lens Composites as Epigallocatechin Gallate Delivery Systems for Inhibition of Bacterial Adhesion
por: Lianghui Zhao, et al.
Publicado: (2021)

Epigallocatechin Gallate: The Emerging Wound Healing Potential of Multifunctional Biomaterials for Future Precision Medicine Treatment Strategies
por: Mazlan Zawani, et al.
Publicado: (2021)

Epigallocatechin-3-gallate pretreatment alleviates doxorubicin-induced ferroptosis and cardiotoxicity by upregulating AMPKα2 and activating adaptive autophagy
por: Huan He, et al.
Publicado: (2021)

Effects of epigallocatechin-3-gallate and acyclovir on herpes simplex virus type 1 infection in oral epithelial cells
por: Ching-Yi Wu, et al.
Publicado: (2021)

An NIR-Triggered Au Nanocage Used for Photo-Thermo Therapy of Chronic Wound in Diabetic Rats Through Bacterial Membrane Destruction and Skin Cell Mitochondrial Protection
por: Jiaxin Ding, et al.
Publicado: (2021)

Polymer-Assisted In Situ Synthesis of Silver Nanoparticles with Epigallocatechin Gallate (EGCG) Impregnated Wound Patch Potentiate Controlled Inflammatory Responses for Brisk Wound Healing
por: Kar AK, et al.
Publicado: (2019)

Effects of Dietary Supplementation with Epigallocatechin Gallate on Meat Quality and Muscle Antioxidant Capacity of Broilers Subjected to Acute Heat Stress
por: Fei Zhao, et al.
Publicado: (2021)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Agnieszka Kaczmarska, et al.
Publicado: (2021)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Reid Oldenburg, MD, PhD, et al.
Publicado: (2022)

(-)-Epigallocatechin-3-Gallate Inhibits eNOS Uncoupling and Alleviates High Glucose-Induced Dysfunction and Apoptosis of Human Umbilical Vein Endothelial Cells by PI3K/AKT/eNOS Pathway
por: Zhang Z, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

(-)-Epigallocatechin-3-Gallate Inhibits eNOS Uncoupling and Alleviates High Glucose-Induced Dysfunction and Apoptosis of Human Umbilical Vein Endothelial Cells by PI3K/AKT/eNOS Pathway [Corrigendum]
por: Zhang Z, et al.
Publicado: (2020)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice
por: Zhongju Lu, et al.
Publicado: (2021)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
por: Yucheol Cheong, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Epigallocatechin-3-gallate protects cardiomyocytes from hypoxia-reoxygenation damage via raising autophagy related 4C expression
por: Ping Liu, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
por: Rashid,Mohammad, et al.
Publicado: (2020)

In vitro study on anti-inflammatory effects of epigallocatechin-3-gallate-loaded nano- and microscale particles
por: Wu YR, et al.
Publicado: (2017)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
por: Mohammed A. S. Abourehab, et al.
Publicado: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
por: YingYing He, et al.
Publicado: (2021)